Multiple biomarkers obtained from liquid biopsy, including soluble PD-L1, circulating immune cells, circulating noncoding RNA, peripheral blood cytokines, and circulating tumor DNA, could predict the responses to ICIs at baseline and monitor changes in the TIME during the treatment.25 Here, CD274 is linked to neoplasm.